Daptomycin > 6 mg/kg/day in complex bone and joint infection

Daptomycin > 6 mg/kg/day in complex bone and joint infection: prospective cohort study in a regional reference center

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN14244698

Enrollment

Registered

2016-01-28

Start date

2011-01-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex bone and joint infection Infections and Infestations

Interventions

A prescription of high doses (>6 mg/kg/day) of daptomycin for complex bone and joint infection. There is only one arm. The total duration is based on the physician decision, and the follow up is based

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with complex BJI managed in the trial participating centre and for whom the need for a treament with daptomycin has been validated in a multidisciplinary meeting

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

Measure	Time frame
Rate of treatment failure that occurred either during the treatment of after the discontinuation of the treatment. Factors associated with treatment failure were determined on univariate Cox analysis and Kaplan-Meier curves.	—

Secondary

Measure	Time frame
Occurence of serious adverse events	—

Countries

France

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026